0
Deep & Emerging Tech·April 15, 2026·1 min read

FDA weighs support for compounding popular peptides

Share

If the FDA greenlights compounding for a subset of peptides, the line between pharma, wellness, and gray-market biohacking blurs fast. Health and longevity startups should assume a more permissive peptide environment and design offerings that survive a later regulatory snapback.